The company managed an eighth consecutive quarter of year-over-year per-test revenue growth as it prepares to enter new markets like minimal residual disease testing.
Prominent players in the market cited maturing validity data and updated guidelines that have led to growing awareness among doctors and patients.
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
The company has already launched a new assay for advanced cancer therapy selection and will make its debut in minimal residual disease later this year.
Velsera to Integrate Arima Genomics Gene Fusion Test in Pierian Clinical Platform
Pierian, now a part of Velsera, is integrating Arima's gene fusion sequencing technology into its NGS analysis, interpretation, and reporting hub.